SynthesisPloS one2025
Changes in individuals' glaucoma progression velocity after IOP-lowering therapy: A systematic review.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Dual Role of Macroglia in Glaucoma: Deciphering the Contributions of Astrocytes and Müller Cells to Retinal Neurodegeneration and Neuroprotection.International journal of molecular sciences · 2026Review
- Complement, Inflammasome, and Microglial Crosstalk in Glaucoma: From Neurodegeneration to Immune-Based Precision Therapy.Life (Basel, Switzerland) · 2026Review
- Molecular and Histological Characterization of a Novel Hydrogel-Based Strategy for Inducing Experimental Glaucoma in Mice.International journal of molecular sciences · 2025Article
- Therapeutic Potential of Tocopherol and Tocotrienol in Glaucoma Management.Drug design, development and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary open-angle glaucoma (POAG) is a chronic progressive optic neuropathy often associated with increased intraocular pressure (IOP). Monitoring glaucoma progression velocity, for example, the rate of change in global indices such as mean deviation (MD), is a common way to determine whether functional deterioration has occurred. This systematic review aims to assess changes in glaucoma progression velocity in response to IOP-lowering therapy at an individual level. A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. A comprehensive search of PubMed, Cochrane CENTRAL, and ClinicalTrials.gov from database inception through November 12, 2023, was conducted for randomized clinical trials involving patients with POAG, normal tension glaucoma, or progressive ocular hypertension who received IOP-lowering therapy with a target IOP reduction ≥20% from baseline. Included trials were required to report visual field progression velocity information for individual patients before and after intervention. One study was found to meet inclusion criteria and, therefore, synthesis of data and meta-analysis were unable to be performed. The study reports on 139 eyes of 109 patients from the Ocular Hypertension Treatment Study who reached a POAG endpoint. In these patients, the post-treatment rate of MD change (-0.27 ± 0.7 dB/year) was significantly slower than the pre-treatment rate (-0.51 ± 0.8), P < 0.01. In addition, the rate of MD change significantly correlated with mean IOP reduction (p < 0.001). The singular study demonstrated that IOP-lowering therapy did variably slow glaucoma progression rate in that patient cohort. There is a need for more studies that focus on individual patients' responses to glaucoma treatment. Furthermore, this information should be used to classify the magnitude of patients' responsiveness to IOP reduction. Future studies should report pre- and post-intervention progression velocities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.